J. Wong, G. Mcquillan, J. Mchutchison, and T. Poynard, Estimating future hepatitis C morbidity, mortality, and costs in the United States, Am J Public Health, vol.90, pp.1562-1569, 2000.

A. Singal and B. Anand, Mechanisms of Synergy Between Alcohol and Hepatitis C Virus, Journal of Clinical Gastroenterology, vol.41, issue.8, pp.761-772, 2007.
DOI : 10.1097/MCG.0b013e3180381584

J. Campbell, H. Hagan, M. Latka, R. Garfein, E. Golub et al., High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities, Drug and Alcohol Dependence, vol.81, issue.3, pp.259-265, 2006.
DOI : 10.1016/j.drugalcdep.2005.07.005

A. Rosman, A. Waraich, K. Galvin, J. Casiano, F. Paronetto et al., Alcoholism is associated with hepatitis C but not hepatitis B in an urban population, Am J Gastroenterol, vol.91, pp.498-505, 1996.

B. Piasecki, J. Lewis, K. Reddy, S. Bellamy, S. Porter et al., Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population, Hepatology, vol.34, issue.4, pp.892-899, 2004.
DOI : 10.1002/hep.1840400419

W. Kim, J. Gross, J. Poterucha, J. Locke, G. Dickson et al., Outcome of hospital care of liver disease associated with hepatitis C in the United States, Hepatology, vol.33, issue.1, pp.201-206, 2001.
DOI : 10.1053/jhep.2001.20798

J. Tsui, M. Pletcher, E. Vittinghoff, K. Seal, and R. Gonzales, Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems, Journal of Hepatology, vol.44, issue.2, pp.262-266, 2006.
DOI : 10.1016/j.jhep.2005.07.027

T. Poynard, P. Bedossa, and P. Opolon, Natural history of liver fibrosis progression in patients with chronic hepatitis C, The Lancet, vol.349, issue.9055, pp.825-832, 1997.
DOI : 10.1016/S0140-6736(96)07642-8

S. Yuen, A. Gogo, J. Luk, I. Cho, C. Ho et al., The Effect of Nicotine and Its Interaction with Carbon Tetrachloride in the Rat Liver, Pharmacology & Toxicology, vol.38, issue.3, pp.225-230, 1995.
DOI : 10.1111/j.1600-0773.1995.tb01017.x

A. Klatsky and M. Armstrong, Alcohol, Smoking, Cofee, and Cirrhosis, American Journal of Epidemiology, vol.136, issue.10, pp.1248-1257, 1992.
DOI : 10.1093/oxfordjournals.aje.a116433

M. Yu, F. Hsu, I. Sheen, C. Chu, D. Lin et al., Prospective Study of Hepatocellular Carcinoma and Liver Cirrhosis in Asymptomatic Chronic Hepatitis B Virus Carriers, American Journal of Epidemiology, vol.145, issue.11, pp.1039-1047, 1997.
DOI : 10.1093/oxfordjournals.aje.a009060

M. Gershwin, C. Selmi, H. Worman, E. Gold, M. Watnik et al., Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients, Hepatology, vol.50, issue.5, pp.1194-1202, 2005.
DOI : 10.1002/hep.20907

C. Zein, K. Beatty, A. Post, L. Logan, S. Debanne et al., Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment, Hepatology, vol.332, issue.6, pp.1564-1571, 2006.
DOI : 10.1002/hep.21423

J. Yuan, S. Govindarajan, K. Arakawa, and M. Yu, Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S., Cancer, vol.101, issue.5, pp.1009-1017, 2004.
DOI : 10.1002/cncr.20427

S. Jee, H. Ohrr, J. Sull, and J. Samet, Cigarette Smoking, Alcohol Drinking, Hepatitis B, and Risk for Hepatocellular Carcinoma in Korea, JNCI Journal of the National Cancer Institute, vol.96, issue.24, pp.1851-1856, 2004.
DOI : 10.1093/jnci/djh334

J. Marrero, R. Fontana, S. Fu, H. Conjeevaram, G. Su et al., Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma, Journal of Hepatology, vol.42, issue.2, pp.218-224, 2005.
DOI : 10.1016/j.jhep.2004.10.005

Z. Chen, B. Liu, J. Boreham, Y. Wu, J. Chen et al., Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs, p.0

Y. Fujita, A. Shibata, I. Ogimoto, Y. Kurozawa, T. Nose et al., The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma, British Journal of Cancer, vol.51, pp.737-739, 2006.
DOI : 10.1002/1097-0142(20010301)91:5<957::AID-CNCR1085>3.0.CO;2-J

F. Pessione, M. Ramond, C. Njapoum, V. Duchatelle, C. Degott et al., Cigarette smoking and hepatic lesions in patients with chronic hepatitis C, Hepatology, vol.34, issue.1, pp.121-125, 2001.
DOI : 10.1053/jhep.2001.25385

A. Dev, K. Patel, A. Conrad, L. Blatt, and J. Mchutchison, Relationship of Smoking and Fibrosis in Patients With Chronic Hepatitis C, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.797-801, 2006.
DOI : 10.1016/j.cgh.2006.03.019

C. Hezode, I. Lonjon, F. Roudot-thoraval, J. Mavier, J. Pawlotsky et al., Impact of smoking on histological liver lesions in chronic hepatitis C, Gut, vol.52, issue.1, pp.126-129, 2003.
DOI : 10.1136/gut.52.1.126

C. Wang, S. Wang, T. Chang, W. Yao, and P. Chou, Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection, Archives of Internal Medicine, vol.162, issue.7, pp.811-815, 2002.
DOI : 10.1001/archinte.162.7.811

E. Jaimes, R. Tian, and L. Raij, Nicotine: the link between cigarette smoking and the progression of renal injury?, AJP: Heart and Circulatory Physiology, vol.292, issue.1, pp.76-82, 2007.
DOI : 10.1152/ajpheart.00693.2006

R. Agarwal, Smoking, oxidative stress and inflammation: Impact on resting energy expenditure in diabetic nephropathy, BMC Nephrology, vol.16, issue.9, p.13, 2005.
DOI : 10.1093/ndt/16.3.556

S. Yang, A. Chida, M. Bauter, N. Shafiq, K. Seweryniak et al., Cigarette smoke induces proinflammatory cytokine release by activation of NF-??B and posttranslational modifications of histone deacetylase in macrophages, AJP: Lung Cellular and Molecular Physiology, vol.291, issue.1, pp.46-57, 2006.
DOI : 10.1152/ajplung.00241.2005

Y. Geng, S. Savage, S. Razani-boroujerdi, and M. Sopori, Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy, J Immunol, vol.156, pp.2384-2390, 1996.

T. Houston, S. Person, M. Pletcher, K. Liu, C. Iribarren et al., Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort: CARDIA study, BMJ, vol.332, issue.7549, pp.1064-1069, 2006.
DOI : 10.1136/bmj.38779.584028.55

F. Anan, N. Takahashi, T. Shinohara, M. Nakagawa, T. Masaki et al., Smoking is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients, European Journal of Clinical Investigation, vol.58, issue.7, pp.459-465, 2006.
DOI : 10.1016/S0895-7061(01)02218-X

G. Leandro, A. Mangia, J. Hui, P. Fabris, L. Rubbia-brandt et al., Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data, Gastroenterology, vol.130, issue.6, pp.1636-1642, 2006.
DOI : 10.1053/j.gastro.2006.03.014

L. Fartoux, O. Chazouilleres, D. Wendum, R. Poupon, and L. Serfaty, Impact of steatosis on progression of fibrosis in patients with mild hepatitis C, Hepatology, vol.34, issue.Suppl 1, pp.82-87, 2005.
DOI : 10.1002/hep.20519

A. Mallat and S. Lotersztajn, Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver, AJP: Gastrointestinal and Liver Physiology, vol.294, issue.1, pp.9-12, 2008.
DOI : 10.1152/ajpgi.00467.2007

A. Mallat and S. Lotersztajn, Endocannabinoids as novel mediators of liver diseases, J Endocrinol Invest, vol.29, pp.58-65, 2006.

P. Pacher, S. Batkai, and G. Kunos, The Endocannabinoid System as an Emerging Target of Pharmacotherapy, Pharmacological Reviews, vol.58, issue.3, pp.389-462, 2006.
DOI : 10.1124/pr.58.3.2

K. Chen and D. Kandel, Predictors of cessation of marijuana use: an event history analysis, Drug and Alcohol Dependence, vol.50, issue.2, pp.109-121, 1998.
DOI : 10.1016/S0376-8716(98)00021-0

W. Swift, W. Hall, and J. Copeland, One year follow-up of cannabis dependence among long-term users in Sydney, Australia, Drug and Alcohol Dependence, vol.59, issue.3, pp.309-318, 2000.
DOI : 10.1016/S0376-8716(99)00131-3

A. Mallat, F. Teixeira-clerc, V. Deveaux, and S. Lotersztajn, Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases, Expert Opinion on Therapeutic Targets, vol.288, issue.3, pp.403-409, 2007.
DOI : 10.1074/jbc.272.35.22330

J. Nhieu, CB2 receptors as new therapeutic targets for liver diseases, Br J Pharmacol, vol.153, pp.286-295, 2008.

D. Piomelli, A. Giuffrida, A. Calignano, and F. Rodriguez-de-fonseca, The endocannabinoid system as a target for therapeutic drugs, Trends in Pharmacological Sciences, vol.21, issue.6, pp.218-224, 2000.
DOI : 10.1016/S0165-6147(00)01482-6

D. Marzo, V. Bifulco, M. , D. Petrocellis, and L. , The endocannabinoid system and its therapeutic exploitation, Nature Reviews Drug Discovery, vol.348, issue.9, pp.771-784, 2004.
DOI : 10.1006/bbrc.1998.8874

B. Julien, P. Grenard, F. Teixeira-clerc, V. Nhieu, J. Li et al., Antifibrogenic role of the cannabinoid receptor CB2 in the liver, Gastroenterology, vol.128, issue.3, pp.742-755, 2005.
DOI : 10.1053/j.gastro.2004.12.050

V. Lanneau, CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis, Nat Med, vol.12, pp.671-676, 2006.

C. Fernandez-rodriguez, J. Romero, T. Petros, H. Bradshaw, J. Gasalla et al., Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis, Liver International, vol.16, issue.5, pp.477-483, 2004.
DOI : 10.1002/hep.510280104

S. Batkai, Z. Jarai, J. Wagner, S. Goparaju, K. Varga et al., Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis, Nature Medicine, vol.7, issue.7, pp.827-832, 2001.
DOI : 10.1038/89953

S. Siegmund, T. Qian, S. De-minicis, J. Harvey-white, G. Kunos et al., The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species, The FASEB Journal, vol.21, issue.11, pp.2798-2806, 2007.
DOI : 10.1096/fj.06-7717com

Y. Yang, H. Lin, Y. Huang, T. Lee, M. Hou et al., cannabinoid receptor antagonism on livers of rats with biliary cirrhosis, Clinical Science, vol.112, issue.10, pp.533-542, 2007.
DOI : 10.1042/CS20060260

C. Hezode, F. Roudot-thoraval, S. Nguyen, P. Grenard, B. Julien et al., 68 Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C, Journal of Hepatology, vol.40, pp.63-71, 2005.
DOI : 10.1016/S0168-8278(04)90068-2

J. Ishida, C. Jin, P. Bacchetti, V. Tan, M. Peters et al., Influence of Cannabis Use on Severity of Hepatitis C Disease, Clinical Gastroenterology and Hepatology, vol.6, issue.1, pp.69-75, 2008.
DOI : 10.1016/j.cgh.2007.10.021

L. Castera, C. Hezode, F. Roudot-thoraval, I. Lonjon, E. Zafrani et al., Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis, Gut, vol.53, issue.3, pp.420-424, 2004.
DOI : 10.1136/gut.2002.009936

T. Asselah, L. Rubbia-brandt, P. Marcellin, and F. Negro, STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?, Gut, vol.55, issue.1, pp.123-130, 2006.
DOI : 10.1136/gut.2005.069757

L. Castera, P. Chouteau, C. Hezode, E. Zafrani, D. Dhumeaux et al., Hepatitis C Virus-Induced Hepatocellular Steatosis, The American Journal of Gastroenterology, vol.116, issue.3, pp.711-715, 2005.
DOI : 10.1016/S0270-9139(03)80647-X

D. Osei-hyiaman, M. Depetrillo, P. Pacher, J. Liu, S. Radaeva et al., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, Journal of Clinical Investigation, vol.115, issue.5, pp.1298-1305, 2005.
DOI : 10.1172/JCI200523057

M. Gary-bobo, G. Elachouri, J. Gallas, P. Janiak, P. Marini et al., Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, vol.330, issue.1, pp.122-129, 2007.
DOI : 10.1002/hep.21641

V. Deveaux, Y. Ichitogani, F. Teixeira-clerc, S. Manin, J. Tran-van-nhieu et al., CB2 receptor antagonism reduces diet-induced obesity, insulin resistance and hepatic steatosis, Hepatology, vol.46, p.308, 2007.

C. Hezode, E. Zafrani, F. Roudot-thoraval, C. Costentin, A. Hessami et al., Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C, Gastroenterology, vol.134, issue.2, 2008.
DOI : 10.1053/j.gastro.2007.11.039